MCUJF
Medicure Inc. [MCUJF] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MCUJF Stock Summary
Top 10 Correlated Stocks
MCUJF
In the News
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing July 28th, 2023.
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
WINNIPEG, MB / ACCESSWIRE / April 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2022 Year End Financial Results on a Conference Call on April 10, 2023 at 8:30 am Eastern Time. The 2022 Year End Financials will be filed after closing on April 6, 2023 ahead of the Good Friday holiday on April 7, 2023 (markets closed).
Medicure Inc. (MCUJF) Q3 2022 Earnings Call Transcript
Medicure Inc. (OTCPK:MCUJF) Q3 2022 Results Conference Call November 25, 2022 8:30 AM ET Company Participants Dr. Albert Friesen - CEO Dr. Neil Owens - President and COO Haaris Uddin - CFO Conference Call Participants Kurt Caramanidis - Carl M. Hennig, Inc. Operator Good morning, ladies and gentlemen and welcome to Medicure's Earnings Conference Call for the Quarter Ended September 30, 2022.
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB , Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB , Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
WINNIPEG, MB , April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call. Conference Call Info: Topic: Medicure's 2021 Year End Results Call date: Thursday, April 28, 2022 Time: 7:30 AM Central Time (8:30 AM Eastern Time) Canada toll: 1 (416) 764-8659 North American toll-free: 1 (888) 664-6392 Passcode: not required Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: www.medicure.com/investors You may request international country-specific access information by e-mailing the Company in advance.
MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario
MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the tie-up, Medx's scanning services are now available to the clinic's 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.
Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript
Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021
WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021. Quarter Ended June 30, 2021 Highlights: Recorded total net revenue from the sale of products of $5.09 million during the second quarter ended June 30, 2021 compared to $2.68 million for the second quarter ended June 30, 2020; Recorded total net revenue from the sale of AGGRASTAT® of $2.8 million during the second quarter ended June 30, 2021 compared to $2.6 million for the second quarter ended June 30, 2020; Net loss for the second quarter ended June 30, 2021 was $639,000 compared to net income of $19,000 for the second quarter ended June 30, 2020; Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA1) for the second quarter ended June 30, 2021 was $158,000 compared to adjusted EBITDA of $263,000 for the second quarter ended June 30, 2020 Financial Results Net revenues for the three months ended June 30, 2021 were $5.09 million compared to $2.68 million for the three months ended June 30, 2020.
Medicure Announces Grant of Stock Options
WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's current stock option plan.
MCUJF Financial details
MCUJF Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.84 | 1.34 | 1.13 | 2.12 | 2.25 | |
| Net income per share | 0.25 | -1.32 | -0.67 | -0.07 | 0.13 | |
| Operating cash flow per share | 0.05 | -0.98 | -0.22 | 0.39 | 0.18 | |
| Free cash flow per share | -0.05 | -1.9 | -0.22 | 0.31 | 0.15 | |
| Cash per share | 4.55 | 0.86 | 0.26 | 0.36 | 0.47 | |
| Book value per share | 5.29 | 1.8 | 1.87 | 1.8 | 2.05 | |
| Tangible book value per share | 5.19 | 1.16 | 0.25 | 0.41 | 0.7 | |
| Share holders equity per share | 5.29 | 1.8 | 1.87 | 1.8 | 2.05 | |
| Interest debt per share | -0.41 | 0.07 | 0.15 | 0.12 | 0.08 | |
| Market cap | 95.32M | 63.6M | 12.24M | 9.54M | 11.17M | |
| Enterprise value | 71.18M | 51.72M | 10.97M | 7.01M | 7.16M | |
| P/E ratio | 24.28 | -3.21 | -1.78 | -13.12 | 8.18 | |
| Price to sales ratio | 3.27 | 3.15 | 1.05 | 0.44 | 0.48 | |
| POCF ratio | 128.41 | -4.34 | -5.46 | 2.39 | 6.11 | |
| PFCF ratio | -129.55 | -2.23 | -5.46 | 3.01 | 7.36 | |
| P/B Ratio | 1.14 | 2.36 | 0.64 | 0.52 | 0.53 | |
| PTB ratio | 1.14 | 2.36 | 0.64 | 0.52 | 0.53 | |
| EV to sales | 2.45 | 2.56 | 0.94 | 0.32 | 0.31 | |
| Enterprise value over EBITDA | -53.15 | -5.87 | -2.43 | 2.73 | 2.13 | |
| EV to operating cash flow | 95.89 | -3.53 | -4.9 | 1.76 | 3.92 | |
| EV to free cash flow | -96.74 | -1.82 | -4.89 | 2.21 | 4.72 | |
| Earnings yield | 0.04 | -0.31 | -0.56 | -0.08 | 0.12 | |
| Free cash flow yield | -0.01 | -0.45 | -0.18 | 0.33 | 0.14 | |
| Debt to equity | 0 | 0.04 | 0.08 | 0.06 | 0.04 | |
| Debt to assets | 0 | 0.03 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | 18.03 | 1.35 | 0.28 | -0.98 | -1.19 | |
| Current ratio | 5.29 | 2.69 | 1.27 | 1.47 | 1.77 | |
| Interest coverage | 0.19 | -487.64 | -148.71 | -15.11 | -56.96 | |
| Income quality | 0.19 | 0.74 | 0.33 | -5.49 | 1.34 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.67 | 0.17 | 0.39 | 0.12 | 0.18 | |
| Research and developement to revenue | 0.23 | 0.22 | 0.28 | 0.08 | 0.12 | |
| Intangibles to total assets | 0.02 | 0.23 | 0.49 | 0.5 | 0.46 | |
| Capex to operating cash flow | -1.99 | 0.95 | 0 | -0.21 | -0.17 | |
| Capex to revenue | -0.05 | -0.69 | 0 | -0.04 | -0.01 | |
| Capex to depreciation | -4.94 | -7.2 | 0 | -0.26 | -0.15 | |
| Stock based compensation to revenue | 0.04 | 0.02 | 0.03 | 0.01 | 0 | |
| Graham number | 5.44 | 7.3 | 5.32 | 1.69 | 2.48 | |
| ROIC | -0.01 | -0.37 | -0.33 | -0.03 | 0.06 | |
| Return on tangible assets | 0.04 | -0.61 | -0.39 | -0.05 | 0.08 | |
| Graham Net | 3.92 | 0.56 | -0.55 | -0.11 | 0.18 | |
| Working capital | 72.65M | 19.7M | 3.37M | 4.04M | 6.46M | |
| Tangible asset value | 81.89M | 17.34M | 2.56M | 4.23M | 7.2M | |
| Net current asset value | 69.42M | 16.02M | 768K | 2.56M | 5.95M | |
| Invested capital | 0 | 0.04 | 0.08 | 0.06 | 0.04 | |
| Average receivables | 51.02M | 10.49M | 7.73M | 4.96M | 5.15M | |
| Average payables | 12.37M | 11.88M | 8.18M | 6.82M | 6.9M | |
| Average inventory | 3.66M | 5.28M | 5.73M | 4.23M | 3.28M | |
| Days sales outstanding | 134.98 | 184.84 | 165.15 | 78.21 | 89.17 | |
| Days payables outstanding | 1.26K | 471.01 | 393.11 | 269.47 | 372.21 | |
| Days of inventory on hand | 372.65 | 317.62 | 289.47 | 134.53 | 168.19 | |
| Receivables turnover | 2.7 | 1.97 | 2.21 | 4.67 | 4.09 | |
| Payables turnover | 0.29 | 0.77 | 0.93 | 1.35 | 0.98 | |
| Inventory turnover | 0.98 | 1.15 | 1.26 | 2.71 | 2.17 | |
| ROE | 0.05 | -0.73 | -0.36 | -0.04 | 0.06 | |
| Capex per share | -0.09 | -0.92 | 0 | -0.08 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.56 | 0.52 | 0.62 | 0.58 | 0.6 | |
| Net income per share | -0.07 | 0.11 | 0.04 | 0.03 | 0.01 | |
| Operating cash flow per share | 0.21 | -0.01 | 0.05 | 0.02 | 0 | |
| Free cash flow per share | 0.2 | -0.02 | 0.04 | 0.02 | 0 | |
| Cash per share | 0.47 | 0.44 | 0.47 | 0.51 | 0.67 | |
| Book value per share | 1.81 | 2.04 | 2.05 | 2.21 | 2.6 | |
| Tangible book value per share | 0.47 | 0.64 | 0.7 | 0.82 | 1.1 | |
| Share holders equity per share | 1.81 | 2.04 | 2.05 | 2.21 | 2.6 | |
| Interest debt per share | 0.1 | 0.09 | 0.12 | 0.08 | 0.07 | |
| Market cap | 10.62M | 9.71M | 11.17M | 10.72M | 12.64M | |
| Enterprise value | 6.8M | 6.16M | 7.16M | 6.57M | 7.62M | |
| P/E ratio | -3.89 | 2.18 | 6.15 | 9.24 | 37.61 | |
| Price to sales ratio | 1.85 | 1.84 | 1.77 | 1.9 | 2.53 | |
| POCF ratio | 4.86 | -80.26 | 22.39 | 61.96 | 0 | |
| PFCF ratio | 5.12 | -42.23 | 24.39 | 73.41 | 0 | |
| P/B Ratio | 0.57 | 0.46 | 0.53 | 0.5 | 0.58 | |
| PTB ratio | 0.57 | 0.46 | 0.53 | 0.5 | 0.58 | |
| EV to sales | 1.18 | 1.17 | 1.13 | 1.17 | 1.52 | |
| Enterprise value over EBITDA | -7.89 | 5.8 | 5.25 | 7.58 | 70.56 | |
| EV to operating cash flow | 3.11 | -50.95 | 14.36 | 37.97 | 0 | |
| EV to free cash flow | 3.28 | -26.8 | 15.64 | 44.99 | 0 | |
| Earnings yield | -0.06 | 0.11 | 0.04 | 0.03 | 0.01 | |
| Free cash flow yield | 0.2 | -0.02 | 0.04 | 0.01 | 0 | |
| Debt to equity | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Net debt to EBITDA | 4.43 | -3.34 | -2.94 | -4.79 | -46.44 | |
| Current ratio | 1.47 | 1.86 | 1.77 | 1.95 | 2.28 | |
| Interest coverage | 20.11 | -16.36 | 2.12 | 65.2 | 0 | |
| Income quality | -3.2 | -0.11 | 1.1 | 0.6 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.27 | 0.2 | 0.04 | 0.16 | 0.2 | |
| Research and developement to revenue | 0.23 | 0.06 | 0.12 | 0.09 | 0.1 | |
| Intangibles to total assets | 0.46 | 0.48 | 0.46 | 0.46 | 0.44 | |
| Capex to operating cash flow | -0.05 | 0.9 | -0.08 | -0.16 | 0 | |
| Capex to revenue | -0.02 | -0.02 | -0.01 | 0 | 0 | |
| Capex to depreciation | -0.22 | -0.21 | -0.08 | -0.05 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
| Graham number | 1.65 | 2.23 | 1.43 | 1.22 | 0.77 | |
| ROIC | -0.04 | 0.02 | 0.04 | 0.01 | 0.01 | |
| Return on tangible assets | -0.04 | 0.07 | 0.03 | 0.02 | 0.01 | |
| Graham Net | -0.04 | 0.13 | 0.18 | 0.3 | 0.54 | |
| Working capital | 4.69M | 6.57M | 6.46M | 7.24M | 8.61M | |
| Tangible asset value | 4.78M | 6.6M | 7.2M | 7.95M | 9.25M | |
| Net current asset value | 3.38M | 5.24M | 5.95M | 6.81M | 8.33M | |
| Invested capital | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | |
| Average receivables | 0 | 5.64M | 5.48M | 5.92M | 0 | |
| Average payables | 0 | 7.32M | 6.73M | 6.79M | 0 | |
| Average inventory | 0 | 3.39M | 3.44M | 3M | 0 | |
| Days sales outstanding | 93.38 | 90.6 | 80.31 | 99.24 | 99.52 | |
| Days payables outstanding | 382.5 | 410.21 | 327.98 | 316.62 | 374.74 | |
| Days of inventory on hand | 144.13 | 236.81 | 148.21 | 136.38 | 223.15 | |
| Receivables turnover | 0.96 | 0.99 | 1.12 | 0.91 | 0.9 | |
| Payables turnover | 0.24 | 0.22 | 0.27 | 0.28 | 0.24 | |
| Inventory turnover | 0.62 | 0.38 | 0.61 | 0.66 | 0.4 | |
| ROE | -0.04 | 0.05 | 0.02 | 0.01 | 0 | |
| Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
MCUJF Frequently Asked Questions
What is Medicure Inc. stock symbol ?
Medicure Inc. is a CA stock , located in Winnipeg of Mb and trading under the symbol MCUJF
What is Medicure Inc. stock quote today ?
Medicure Inc. stock price is $1.04 today.
Is Medicure Inc. stock public?
Yes, Medicure Inc. is a publicly traded company.
Company Profile
- Volume Average 2.04K
- Market Capitalization 10.85M
- CEO Dr. Albert David Friesen Ph.D.
- Headquarters Winnipeg,MB,CA
- IPO Date 2004-02-19
-
Website
https://www.medicure.com 
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
